During vasculitis month we spoke to patients and carers to hear their real-world experiences with AAV first hand.
John & Susan
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; EU, European Union; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; UK, United Kingdom; US, United States
*Patients (n=33; <40 years: 9.1%; 40–60 years: 48.5%; 60–79 years: 39.4%; ≥80 years: 3.0%) recruited from four EU countries with a confirmed diagnosis of GPA (60.6%), MPA (36.4%) or EGPA (3.0%) for ≥12 months who had received ≥1 course of induction therapy to achieve remission and completed 1:1 interviews;1,2 †Patients (n=50; ≥50 years: 80%; male: 48%) with GPA (52%), MPA (14%) or EGPA (36%) recruited from three rheumatology centres in the UK, US and Canada who completed interviews with their answers probed as appropriate.3
Rutherford P, et al. Patient experience in ANCA-associated vasculitis evolves over time from diagnosis and both benefits and adverse impacts are felt with current therapy. Poster presented at: ACR/ARHP 2018, 19–24 October 2018, Chicago, IL, USA (abstract 2723).
Rutherford P, et al. Patient experience in anti-neutrophil cytoplasmic antibody-associated vasculitis – evolution with time and impact of current therapy. Draft publication.
Robson JC, et al. Rheumatol Int 2018;38(4):675–82.